ArticleFuture oncology (London, England)2026
The broad societal value of pembrolizumab for women's cancer in Canada.
Article in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe impact of women's cancers is multifaceted, with broad societal and economic consequences. Health technology assessments often rely solely on costs and outcomes directly relevant to the healthcare system. Our study incorporates the additional and novel value elements across three perspectives for pembrolizumab in four women's cancers in a Canadian setting. PATIENTS AND
methodsWe analyzed the net monetary benefit (NMB) of pembrolizumab-based treatments of early-stage triple-negative breast cancer, metastatic triple-negative breast cancer, microsatellite instability-high endometrial cancer, and cervical cancer from three perspectives: traditional payer perspective (TPP), traditional societal perspective (TSP), and broad societal perspective (BSP). Indications and comparators were modeled independently, combined, and weighted by prevalence.
resultsPembrolizumab-based therapy generated an NMB over four times greater with the BSP (Canadian dollars, CAD$925,078), compared with TPP (CAD$226,090) and TSP (CAD$222,556). The largest driver of results was the inclusion of insurance value. Results excluding insurance value still generated an NMB of CAD$484,384, more than twice the TPP.
conclusionsBroadening the perspective to include additional value elements considerably increased the overall value of treatment of women's cancer compared with the TPP, indicating that the perspective used by health technology bodies may not fully capture the societal value of therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.